MEDICAL DEVICE NEWS MAGAZINE

Tuesday, September 27, 2022

MEDICAL DEVICE NEWS MAGAZINE

|

Contact us 561.316.3330

Lumenis Introduces Stellar M22™

Stellar M22™ is Now available in the USA and Europe

Lumenis, the inventor of IPL, is proud to introduce the next generation in Multi-Application platforms, The Stellar M22™. This system offers everything users need in one platform, while making both the physician and patient experience more seamless and successful than ever before.

Lumenis notes the launch continues Lumenis’ mission to improve the standard of care in the ever-growing, multi-billion-dollar energy-based skincare market.

“Lumenis is the pioneer in IPL, from the PhotoDerm to the M22, all of which were and are the gold standard,” said Dr. Mitchel Goldman from San Diego, California. “The Stellar M22’s efficiency is second-to-none with improved patient comfort, speed, versatility, reliability and results with better outcomes. At the end of the day, we offer patients treatments that work, which translates into increased patient satisfaction and increased profitability,” continued Dr. Goldman.

The Stellar M22 is built and based upon the gold standard of Lumenis’ original M22, and continues to carry out all treatment capabilities (i.e. treatment of vascular lesions, skin texture, tone, and hair removal) but with upgrades that make for a further amplified experience.

“The new Stellar M22™ IPL allows for easy and quick treatment with the great output and efficacy we already know from Lumenis,” said Dr. Tretti Clementoni, from Milan, Italy. He continued, “It is a huge time saver and the results are stellar!”

The latest leaps of the sixth generation IPL, Stellar M22™ include a dramatically improved user interface with a larger screen that enables a faster treatment time and more comfortable viewing from a distance. In addition, the Stellar M22™ provides a new ergonomic IPL hand piece design and longer SapphireCool™ Lightguides for better visibility of the treatment area.

“Lumenis is thrilled to introduce the new Stellar M22™, our next-generation in multi-application devices, enabling treatment of over 30 skin conditions and hair removal across skin type, gender and age,” said Tzipi Ozer-Armon, CEO of Lumenis. “Like the M22 before it, Stellar redefines the benchmark in the category and demonstrates our continued commitment to innovation and better technology for better patient care.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.
Subscribe to Medical Device News Magazine

Prodeon Medical Announces Randomization in the Expander-2 Pivotal Clinical Trial Evaluating the Company’s Investigational Treatment for Lower Urinary Tract Symptoms Associated to Benign Prostatic Hyperplasia

The first randomization was performed by Mark Sutton, M.D., F.A.C.S. at Houston Metro Urology in Houston, TX. Dr. Sutton specializes in comprehensive urologic services for men and women including BPH notes Prodeon Medical.

XRHealth Reports Clinical Trial Finds that Virtual Reality Therapy May Serve as Effective Adjunct To Anesthesia For Surgical Procedures

XRHealth notes the findings could lead to a discussion in the medical industry about using non-pharmaceutical interventions during surgical procedures that both enhance the patient experience during surgery and provide a better postoperative recovery.

New Study Suggests REN Comparable to Standard Care Prescribed Medications for Acute Treatment of Chronic Migraines

Prospective data from 78 adult patients with chronic migraines in the U.S. demonstrated effectiveness of REN across four parameters in comparison to standard-care medications.

By using this website you agree to accept Medical Device News Magazine Privacy Policy